Medicines and Healthcare products Regulatory Agency

CERTIFICATE NUMBER: UK API 4 Insp GMP 4/15697-0019

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER (1),(2)

Part 1

Issued following an inspection in accordance with:

Regulation 331A of The Human Medicines Regulations 2012 (SI 2012/1916)

The competent authority of United Kingdom confirms the following:

The Manufacturer: GLAXO OPERATIONS UK LTD TRADING AS GLAXO WELLCOME OPERATIONS

Site address: GLAXO OPERATIONS UK LTD TRADING AS GLAXO WELLCOME OPERATIONS, NORTH LONSDALE ROAD, ULVERSTON, LA12 9DR, UNITED KINGDOM

Is an active substance manufacturer that has been inspected in accordance with Regulation 327 of The Human Medicines Regulations 2012 (SI 2012/1916).

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 22/05/2017, it is considered that it complies with

• The principles of GMP for active substances referred to in Regulation B17 and C17 of the Human Medicines Regulations 2012 (SI 2012/1916)

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in MHRA-GMDP. If it does not appear, please contact the issuing authority.

- (1) Guidance on the interpretation of this template can be found in the Help menu of MHRA-GMDP database.
- (2) These requirements fulfil the GMP recommendations of WHO.

Part 2

Human Medicinal Products

Manufacture of active substance. Names of substances subject to inspection :

- [2000008119] CEFTAZIDIME PENTAHYDRATE
- [2000015677] AVIBACTAM SODIUM
- [2000008117] CEFUROXIME AXETIL
- [2000008116] CEFUROXIME SODIUM
- 3. MANUFACTURING OPERATIONS ACTIVE SUBSTANCES

Page 1 of 4

CEFTAZIDIME PENTAHYDRATE

CEFTAZIDIME PENTAHYDRA	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture Of Active Substance Intermediates
	3.1.2 Manufacture Of Crude Active Substance
	3.1.3 Salt Formation/Purification steps (eg. Crystallisation) Not specified
3.4	Manufacture of sterile active substance
	3.4.1 Aseptically prepared
3.5	General Finishing Steps
	3.5.1 Physical Processing Steps
	Crystallisation, filtration and drying
	3.5.2 Primary Packaging
	3.5.3 Secondary Packaging
3.6	Quality Control Testing
19.	3.6.1 Physical / Chemical testing
	3.6.3 Microbiological testing (including sterility testing)
AVIBACTAM SODIUM	
AVIBACTAM SODIUM 3.1	Manufacture of Active Substance by Chemical Synthesis
	Manufacture of Active Substance by Chemical Synthesis 3.1.1 Manufacture Of Active Substance Intermediates
	3.1.1 Manufacture Of Active Substance Intermediates
	3.1.1 Manufacture Of Active Substance IntermediatesOther highly sensitising antibiotics3.1.3 Salt Formation/Purification steps (eg. Crystallisation)
	3.1.1 Manufacture Of Active Substance IntermediatesOther highly sensitising antibiotics3.1.3 Salt Formation/Purification steps (eg. Crystallisation)Crystallisation, drying
3.1	3.1.1 Manufacture Of Active Substance IntermediatesOther highly sensitising antibiotics3.1.3 Salt Formation/Purification steps (eg. Crystallisation)Crystallisation, dryingOther highly sensitising antibiotics
3.1	3.1.1 Manufacture Of Active Substance Intermediates Other highly sensitising antibiotics 3.1.3 Salt Formation/Purification steps (eg. Crystallisation) Crystallisation, drying Other highly sensitising antibiotics Manufacture of sterile active substance
3.1	3.1.1 Manufacture Of Active Substance Intermediates Other highly sensitising antibiotics 3.1.3 Salt Formation/Purification steps (eg. Crystallisation) Crystallisation, drying Other highly sensitising antibiotics Manufacture of sterile active substance 3.4.1 Aseptically prepared
3.4	3.1.1 Manufacture Of Active Substance Intermediates Other highly sensitising antibiotics 3.1.3 Salt Formation/Purification steps (eg. Crystallisation) Crystallisation, drying Other highly sensitising antibiotics Manufacture of sterile active substance 3.4.1 Aseptically prepared Other highly sensitising antibiotics General Finishing Steps 3.5.1 Physical Processing Steps
3.4	3.1.1 Manufacture Of Active Substance Intermediates Other highly sensitising antibiotics 3.1.3 Salt Formation/Purification steps (eg. Crystallisation) Crystallisation, drying Other highly sensitising antibiotics Manufacture of sterile active substance 3.4.1 Aseptically prepared Other highly sensitising antibiotics General Finishing Steps 3.5.1 Physical Processing Steps Drying, milling
3.4	3.1.1 Manufacture Of Active Substance Intermediates Other highly sensitising antibiotics 3.1.3 Salt Formation/Purification steps (eg. Crystallisation) Crystallisation, drying Other highly sensitising antibiotics Manufacture of sterile active substance 3.4.1 Aseptically prepared Other highly sensitising antibiotics General Finishing Steps 3.5.1 Physical Processing Steps Drying, milling Other highly sensitising antibiotics
3.4	3.1.1 Manufacture Of Active Substance Intermediates Other highly sensitising antibiotics 3.1.3 Salt Formation/Purification steps (eg. Crystallisation) Crystallisation, drying Other highly sensitising antibiotics Manufacture of sterile active substance 3.4.1 Aseptically prepared Other highly sensitising antibiotics General Finishing Steps 3.5.1 Physical Processing Steps Drying, milling
3.4	3.1.1 Manufacture Of Active Substance Intermediates Other highly sensitising antibiotics 3.1.3 Salt Formation/Purification steps (eg. Crystallisation) Crystallisation, drying Other highly sensitising antibiotics Manufacture of sterile active substance 3.4.1 Aseptically prepared Other highly sensitising antibiotics General Finishing Steps 3.5.1 Physical Processing Steps Drying, milling Other highly sensitising antibiotics
3.4	3.1.1 Manufacture Of Active Substance Intermediates Other highly sensitising antibiotics 3.1.3 Salt Formation/Purification steps (eg. Crystallisation) Crystallisation, drying Other highly sensitising antibiotics Manufacture of sterile active substance 3.4.1 Aseptically prepared Other highly sensitising antibiotics General Finishing Steps 3.5.1 Physical Processing Steps Drying, milling Other highly sensitising antibiotics 3.5.2 Primary Packaging

2.0	Overlite Countrel Testine			
3.6	Quality Control Testing			
	3.6.1 Physical / Chemical testing			
	Other highly sensitising antibiotics			
	3.6.3 Microbiological testing (including sterility testing)			
OFFUDOVIME AVETU	Other highly sensitising antibiotics			
CEFUROXIME AXETIL				
3.1	Manufacture of Active Substance by Chemical Synthesis			
	3.1.1 Manufacture Of Active Substance Intermediates			
	3.1.2 Manufacture Of Crude Active Substance			
	3.1.3 Salt Formation/Purification steps (eg. Crystallisation)			
	Not specified			
3.5	General Finishing Steps			
	3.5.1 Physical Processing Steps			
	Spray drying			
	3.5.2 Primary Packaging			
171,				
	3.5.3 Secondary Packaging			
3.6	Quality Control Testing			
	3.6.1 Physical / Chemical testing			
CEFUROXIME SODIUM				
3.1	Manufacture of Active Substance by Chemical Synthesis			
	3.1.1 Manufacture Of Active Substance Intermediates			
	3.1.2 Manufacture Of Crude Active Substance			
	3.1.3 Salt Formation/Purification steps (eg. Crystallisation) Not Specified			
3.4	Manufacture of sterile active substance			
	3.4.1 Aseptically prepared			
3.5	General Finishing Steps			
	3.5.1 Physical Processing Steps			
	Crystallisation, filtration and drying			
	3.5.2 Primary Packaging			
	2.5.2. Casandam, Basharita			
~ <i>U</i> // ,	3.5.3 Secondary Packaging			
3.6	Quality Control Testing			
5.0	Quality Control 165th			

3.6.1 Physical / Chemical testing

3.6.3 Microbiological testing (including sterility testing)

Any restrictions related to the scope of this certificate:

Building	R	oom	Line/equipment	QC Testing	Products	
This inspection	on cover Buildings 11 and 14.	17				
		\boldsymbol{T}				
07/07/2017	Name and signature of the authorised person of the Competent Authority of United Kingdom					
	Confidential					
	Medicines and Healthcare products Regulatory Age	ency				
	Tel : Confidential					